4769f22f-eeaf-4108-9555-55cc5d6ae27b
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.630
- INTERFERON_ALPHA_RESPONSE+0.470
- FATTY_ACID_METABOLISM+0.460
- PEROXISOME+0.450
- CHOLESTEROL_HOMEOSTASIS+0.390
- MTORC1_SIGNALING+0.390
- P53_PATHWAY+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- MYC_TARGETS_V1+0.350
- MYC_TARGETS_V2+0.340
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
- HEDGEHOG_SIGNALING-0.440
- ANGIOGENESIS-0.380
- MYOGENESIS-0.350
- UV_RESPONSE_DN-0.300
- APICAL_JUNCTION-0.260
- WNT_BETA_CATENIN_SIGNALING-0.200
- NOTCH_SIGNALING-0.180
- HYPOXIA-0.160
- COAGULATION-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | db087000-74fa-4044-812f-01842b99f448 | — | — | 0.862 |
| 2 | f4aa57d8-df4c-4fee-979a-0f981c8762da | — | — | 0.859 |
| 3 | a8e85cdd-3770-40a0-837e-6962ec12fcf0 | — | — | 0.845 |
| 4 | c340b651-bd01-4194-a67b-e801d0feeb2b | — | — | 0.844 |
| 5 | bf312cd5-e251-4d63-95b5-c379b3ef5ded | — | — | 0.830 |
| 6 | bc895549-854b-484f-8a6d-9e5152829bcb | — | — | 0.829 |
| 7 | 2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd | — | — | 0.816 |
| 8 | TCGA-AR-A0TW-01A-11R-A084-07 | — | B | 0.813 |
| 9 | TCGA-CV-5439-01A-01R-1686-07 | — | — | 0.800 |
| 10 | 1a68a242-045b-4566-afd7-192df87b02d3 | — | — | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.630 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.460 | Inavolisib | — uncovered |
| PEROXISOME | 0.450 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.390 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.390 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |